Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 13 May, 2014

Grantham, Mayo, Van

Form 8.3 -Astrazeneca Plc

RNS Number : 9927G
Grantham, Mayo, Van Otterloo LLC
13 May 2014
 



FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1.         KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed:

Grantham, Mayo, Van Otterloo & Co. LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

     The naming of nominee or vehicle companies is insufficient


(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

     Use a separate form for each offeror/offeree

Astrazeneca Plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:


(e) Date position held/dealing undertaken:

12 May 2014

(f)  Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

yes

If YES, specify which:

Pfizer Inc

 

2.         POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

17,820,969

1.4118



(2) Derivatives (other than options):





(3) Options and agreements to purchase/sell:

200,000

.0158

200,000

.0158

 

     TOTAL:

18,020,969

1.4276

200,000

0.0158

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b)        Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:


Details, including nature of the rights concerned and relevant percentages:


 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3.         DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a)        Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

USD

Ordinary

SALE

2882

46.1433

Ordinary

SALE

11608

46.1433

Ordinary

SALE

17369

46.1433

Ordinary

SALE

2362

46.1433

Ordinary

SALE

148

46.1433

Ordinary

SALE

1524

46.1433

Ordinary

SALE

326

46.1433

Ordinary

SALE

1028

46.1433

Ordinary

SALE

777

46.1433

Ordinary

SALE

2475

46.1433

Ordinary

SALE

1059

46.1433

Ordinary

SALE

26419

46.1433

Ordinary

SALE

90113

46.1433

Ordinary

SALE

522

46.1433

Ordinary

SALE

1862

46.1433

Ordinary

SALE

2229

46.1433

Ordinary

SALE

5192

46.2446

Ordinary

SALE

1085

46.1433

Ordinary

SALE

2004

46.1433

Ordinary

SALE

3257

46.1433

Ordinary

SALE

4143

46.1433

Ordinary

SALE

124

46.1433

Ordinary

SALE

6084

46.1433

Ordinary

SALE

5200

46.1433

Ordinary

SALE

1220

46.1433

Ordinary

SALE

160

46.1433

Ordinary

SALE

126

46.1433

Ordinary

SALE

22344

46.1433

Ordinary

SALE

697

46.1433

Ordinary

SALE

3014

46.1433

 

(b)        Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit


 

 




 

(c)        Options transactions in respect of existing securities

 

(i)         Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit









 

(ii)        Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit




 

 

 

(d)        Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)


 

 



 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4.         OTHER INFORMATION

 

(a)        Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b)        Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i)  the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c)        Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES

 

 

Date of disclosure:

13 May 2014

Contact name:

Laura McLaughlin

Telephone number:

0016177905054

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at [email protected].  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 



 

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1.         KEY INFORMATION

 

Identity of person whose open positions are being disclosed:

Grantham, Mayo, Van Otterloo & Co. LLC

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

Astrazeneca Plc

 

2.         OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option

Put

Written

50,000

75

American

17/1/2015

Option

Put

Written

50,000

75

American

17/1/2015

Option

Call

Written

50,000

80

American

17/1/2015

Option

Call

Written

50,000

80

American

17/1/2015

Option

Put

Written

50,000

75

American

21/6/2014

Option

Put

Written

50,000

75

American

21/6/2014

Option

Call

Written

50,000

75

American

21/6/2014

Option

Call

Written

50,000

75

American

21/6/2014

 

3.         AGREEMENTS TO PURCHASE OR SELL ETC.

 

Full details should be given so that the nature of the interest or position can be fully understood:

 

 

 

 

 

 

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.

 

The currency of all prices and other monetary amounts should be stated.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETLLFLVETIVLIS

a d v e r t i s e m e n t